Collegium Appoints Vikram Karnani as Chief Executive Officer

COLL 11.07.2024

Full Press ReleaseSEC FilingsOur COLL Tweets

About Gravity Analytica

Recent News

  • 01.08.2025 - Collegium Provides 2025 Financial Guidance and Business Update
  • 12.05.2024 - Piper Sandler 36th Annual Healthcare Conference
  • 11.19.2024 - Jefferies London Healthcare Conference

Recent Filings

  • 01.14.2025 - 4 Statement of changes in beneficial ownership of securities
  • 01.10.2025 - 144 Report of proposed sale of securities
  • 01.08.2025 - 8-K Current report
Vikram Karnani is a Proven Industry Leader with Extensive Experience Growing Commercial Biopharmaceutical Businesses

STOUGHTON, Mass.,Nov. 07, 2024(GLOBE NEWSWIRE) --Collegium Pharmaceutical, Inc.(Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced thatVikram Karnanihas been appointed as President and Chief Executive Officer (CEO) of Collegium and will join its Board of Directors effectiveNovember 12, 2024.Michael Heffernan, who has served as Interim President and CEO sinceMay 2024, will remain Chairman of the Board.

Mr. Karnanihas more than 15 years of leadership experience in the life sciences industry. Over the course of nearly a decade at Horizon Therapeutics,Mr. Karnaniheld leadership positions spanning many aspects of the business, including leading Horizon’s growth strategy and its transformation into a leader in rare disease medicines as well as establishing and expanding Horizon’s presence in international markets. This culminated in his leadership of the integration of the Horizon rare disease business into Amgen following the acquisition in 2023. During his tenure, annual net product sales grew from approximately$300 millionto nearly$4 billion.

“Vikram’s demonstrated success in building organizations and maximizing their potential through both organic growth and business development makes him the right fit to lead Collegium through its next phase of growth,” saidMr. Heffernan. “The outlook for Collegium has never been stronger. With our pain portfolio delivering record revenue and Jornay PM®poised to become our lead growth driver, we are well positioned, with Vikram as our new CEO, for continued success in 2025 and beyond.”

“Collegium is a leader in specialty pharmaceuticals with an impressive track record of commercial growth and capital deployment and has a talented team dedicated to improving the lives of people living with serious medical conditions,” saidMr. Karnani. “Collegium’s leadership in responsible pain management and recent expansion into neurology underscore the Company’s significant growth prospects and ability to generate value for shareholders. I am excited to join Collegium at this pivotal time and work with this accomplished team to lead the business as we build a leading, diversified specialty pharmaceutical company.”

Vikram Karnanimost recently served as Executive Vice President and President, Global Commercial Operations and Medical Affairs (Rare Disease) at Amgen, where he was responsible for driving the global commercial strategy for Amgen’s portfolio of rare disease medicines. Prior to joining Amgen through its 2023 acquisition of Horizon,Mr. Karnaniheld numerous roles of increasing responsibility at Horizon that culminated in his position as Executive Vice President and President of Global Commercial and Medical Affairs, responsible for Horizon’s portfolio of rare disease medicines. Before joining Horizon in 2014,Mr. Karnaniserved as Vice President of the Therapeutics andCell Therapybusiness and held leadership roles in strategy and business development at Fresenius Kabi.Mr. Karnanihas a Master of Business Administration fromKellogg School of ManagementatNorthwestern University, a Master of Science in Electrical Engineering fromCase Western Reserve Universityand a Bachelor’s degree in Electrical Engineering fromUniversity of MumbaiinIndia.

AboutCollegium Pharmaceutical, Inc.

Collegium is a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions. Collegium’s headquarters are located in Stoughton,Massachusetts. For more information, please visit the Company’s website atwww.collegiumpharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Examples of forward-looking statements contained in this press release include, among others, statements related to our aspirations for the performance of our newly appointed executive and expectations relating to our future financial performance and growth. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results, performance, or achievements to differ materially from the company's current expectations, including risks relating to, among others: unknown liabilities; risks related to future opportunities and plans for our products, including uncertainty of the expected financial performance of such products; our ability to commercialize and grow sales of our products; our ability to successfully integrate the operations ofIronshoreinto our organization, and realize the anticipated benefits associated with the acquisition; our ability to manage our relationships with licensors; the success of competing products that are or become available; our ability to maintain regulatory approval of our products, and any related restrictions, limitations, and/or warnings in the label of our products; the size of the markets for our products, and our ability to service those markets; our ability to obtain reimbursement and third-party payor contracts for our products; the rate and degree of market acceptance of our products; the costs of commercialization activities, including marketing, sales and distribution; changing market conditions for our products; the outcome of any patent infringement or other litigation that may be brought by or against us; the outcome of any governmental investigation related to our business; our ability to secure adequate supplies of active pharmaceutical ingredient for each of our products and manufacture adequate supplies of commercially saleable inventory; our ability to obtain funding for our operations and business development; regulatory developments in the U.S.; our expectations regarding our ability to obtain and maintain sufficient intellectual property protection for our products; our ability to comply with stringent U.S. and foreign government regulation in the manufacture of pharmaceutical products, including U.S. Drug Enforcement Agency, or DEA, compliance; our customer concentration; and the accuracy of our estimates regarding expenses, revenue, capital requirements and need for additional financing. These and other risks are described under the heading "Risk Factors" in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and other filings with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Investor Contact:Danielle JesseDirector, Investor Relationsir@collegiumpharma.com

Media Contact:Marissa SamuelsVice President, Corporate Communicationscommunications@collegiumpharma.com

Primary Logo

Source: Collegium Pharmaceutical, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com